Fosun Pharma (600196.SH) subsidiary's drug HLX105 receives clinical trial approval

date
16/11/2026
Zhitong Finance APP news, Fosun Pharma (600196.SH) announced that recently, the company's controlled subsidiary Shanghai Henlius Biotech, Inc. and its controlled subsidiaries (collectively "Henlius") received approval from the National Medical Products Administration for the Phase I clinical trial of HLX105 for injection (i.e., an antibody fusion protein of a PD-1 antibody fused with an IL-2 variant, referred to as "HLX105") for the treatment of advanced/metastatic solid tumors. Henlius plans to conduct the relevant clinical research of this drug in China1 once conditions are met.